A Phase II Study of Vismodegib plus Radiation Therapy for Locally Advanced Basal Cell Cancers of the Head and Neck

Full Title

A Phase II Study of Radiation Therapy and Vismodegib, for the Treatment of Locally Advanced Basal Cell Carcinoma of the Head and Neck

Purpose

Basal cell carcinoma of the head and neck is most often treated with surgery and/or radiation therapy. In some cases, surgery may not be possible. The purpose of this study is to see if giving the anticancer drug vismodegib plus radiation therapy can eliminate locally advanced basal cell cancer of the head and neck that cannot be surgically removed and to see if this treatment can prevent the spread of the cancer to other parts of the body.

Vismodegib is already approved for treating basal cell cancers of the skin that cannot be treated with surgery or radiation or have spread throughout the body, but its use in this study is considered investigational. Vismodegib is a capsule that is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have locally advanced basal cell carcinoma of the head and neck that cannot be surgically removed.
  • Patients with metastatic basal cell carcinoma may not participate.
  • Prior radiation therapy is allowed, but not to the same area that would be irradiated in this study.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Christopher Barker at 212-639-8168.

Protocol

14-022

Phase

II

Investigator

Co-Investigators